When the Confirmatory Trial Fails: What ADC Therapeutics' Zynlonta Data Mean for the Accelerated Approval Era

The antibody-drug conjugate field has spent the past several years accumulating wins. From Enhertu's remarkable performance across multiple tumor types to the recent Phase 3 data showing sacituzumab tirumotecan outperforming pembrolizumab monotherapy in first-line lung cancer, ADCs have become the most talked-about drug class in oncology. Against that backdrop, the data that ADC Therapeutics released on June 3, 2026 from its LOTIS-5 confirmatory trial landed with particular force. Not because the drug failed to show any benefit, but because of what the safety data revealed, and what that revelation says about the risks embedded in the accelerated approval pathway.

What the LOTIS-5 Data Actually Show

The LOTIS-5 trial enrolled 440 patients with relapsed or refractory diffuse large B cell lymphoma who had undergone at least one prior line of systemic therapy. They were randomized to receive either Zynlonta (loncastuximab tesirine-lpyl) combined with rituximab, or a standard regimen of rituximab plus gemcitabine and oxaliplatin. The trial was designed as the confirmatory study required to convert Zynlonta's accelerated approval, granted by the FDA in April 2021 for third-line or later DLBCL, into a full approval, potentially in an earlier line of treatment.

The primary endpoint, progression-free survival, was met. Patients on the Zynlonta combination saw a 27 percent reduction in the risk of disease progression or death compared to the control arm. Overall and complete response rates were also higher in the Zynlonta group. On those measures, the drug performed. The problem was the mortality signal. In the Zynlonta arm, 27 patients died as treatment-emergent adverse events, compared with nine deaths in the control group. That is three times as many deaths in the experimental arm. The company noted that a majority of the deaths occurred in patients aged 75 and older, and attributed the elevated TEAE observation time in the Zynlonta arm as a contributing factor. But the overall survival analysis showed no benefit for patients receiving the Zynlonta regimen, and analysts at Stephens described the safety signal as strongly elevated and the efficacy readout as underwhelming relative to expectations.

ADC Therapeutics' share price fell more than 50 percent on the news, closing at $1.44. The company said it plans to discuss the LOTIS-5 data with the FDA and intends to submit a supplemental application for full approval in the fourth quarter of 2026.

The Accelerated Approval Bargain and Its Costs

To understand why this result matters beyond ADC Therapeutics itself, it helps to revisit what accelerated approval is designed to do and what it implicitly asks of patients. The pathway allows the FDA to approve drugs based on surrogate endpoints, such as response rate or progression-free survival, that are reasonably likely to predict clinical benefit, rather than waiting for definitive overall survival data. The logic is sound: for patients with serious diseases and limited options, earlier access to a promising drug is worth the uncertainty. The cost of that bargain is the confirmatory trial, which is supposed to verify that the surrogate benefit translates into something patients actually care about, namely living longer.

Zynlonta's accelerated approval in 2021 was based on a single-arm trial showing a 48.3 percent overall response rate in heavily pretreated DLBCL patients. That was a meaningful signal in a population with few options. What LOTIS-5 was supposed to establish was whether that signal held up in a randomized comparison, in an earlier line of treatment, against an active control. The PFS benefit suggests the drug does something. The mortality imbalance raises a harder question: does it do enough of the right things, for the right patients, to justify its toxicity profile in a broader population?

That question is not unique to Zynlonta. The FDA has been grappling with the accelerated approval framework for years, and the agency has moved to tighten requirements for confirmatory trials following several high-profile cases where drugs approved on surrogate endpoints failed to demonstrate survival benefit or showed unexpected harm in follow-up studies. The LOTIS-5 result adds another data point to that ongoing reckoning.

What This Means for the ADC Field

The broader ADC landscape is not threatened by this result, but it is usefully complicated by it. The class has generated genuine breakthroughs, and the mechanism of delivering cytotoxic payloads directly to tumor cells expressing a target antigen remains scientifically compelling. What LOTIS-5 illustrates is that not all ADCs are created equal, and that the design choices embedded in each molecule, the target antigen, the linker chemistry, the payload, and the drug-to-antibody ratio, have real consequences for the balance between efficacy and toxicity.

Loncastuximab tesirine uses a pyrrolobenzodiazepine dimer payload, a highly potent DNA-crosslinking agent. PBD-based payloads have been associated with significant toxicity in other programs, and the LOTIS-5 mortality signal may reflect the cumulative burden of that payload in an older patient population receiving a longer course of treatment than the control arm. Whether the toxicity is manageable in a more carefully selected population, or whether the drug's benefit-risk profile is simply unfavorable in the second-line setting, is a question the FDA discussion will need to address.

For investors and industry observers, the LOTIS-5 result is a reminder that the ADC boom has been built on a relatively small number of highly successful programs, and that the class's track record of success does not guarantee that every ADC will replicate it. The drugs that have defined the field, Enhertu, Trodelvy, and now sacituzumab tirumotecan, share a combination of well-validated targets, optimized linker-payload designs, and clinical development strategies that matched the drug's mechanism to the right patient population. Programs that lack one or more of those elements face a harder road, regardless of the class's overall momentum.

A Necessary Correction

There is a version of this story that frames the LOTIS-5 result as a failure of the accelerated approval system. That framing is too simple. The system worked as designed: a drug with a promising early signal received conditional approval, patients gained access to it, and a confirmatory trial was conducted to test whether the promise held. The answer, in this case, is complicated. The PFS benefit is real. The mortality imbalance is also real. The FDA and ADC Therapeutics will now have to work through what that combination means for the drug's future.

What the result does underscore is that the confirmatory trial requirement is not a formality. It is the mechanism by which the accelerated approval bargain is settled, and the data it generates can be uncomfortable. In a field that has grown accustomed to celebrating ADC successes, the LOTIS-5 data are a useful corrective. The science of targeted drug delivery is advancing rapidly. The clinical judgment required to deploy that science safely, in the right patients, at the right dose, in the right line of treatment, is advancing more slowly. That gap is where the hard work of oncology drug development actually lives.